Application of genomic technologies to human prostate cancer.
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in U.S. males and has a broad spectrum of clinical behavior ranging from indolent to lethal. Microarray technology has provided unprecedented opportunity to explore the genetic processes underlying prostate cancer by providing a comprehensive survey of a cell's transcriptional landscape. Prostate cancer, however, has posed significant challenges that have contributed to inconsistent results between studies and difficulty replicating findings. Despite these challenges, several important insights have been gained along with new clinical biomarkers of diagnosis and prognosis. Continued improvements in methods of tissue preparation, microarray technology and data analysis will overcome existing challenges and fuel future discoveries.
Li
Shijun
S
Department of Urology, Stanford University of Medicine, Stanford, California 94305-5118, USA.
Bhamre
Suvarna
S
Lapointe
Jacques
J
Pollack
Jonathan R
JR
Brooks
James D
JD
D020869:Gene Expression Profiling; D023281:Genomics / Q000379:methods*; D006801:Humans; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics*